Ascension bet $3.9B on AmSurg's surgery centers to extend its turnaround to 25 new markets

Speaking at the January 2026 J.P. Morgan Healthcare Conference, Ascension CEO Eduardo Conrado framed the system's $3.9 billion agreement to acquire AmSurg — 250-plus managed ambulatory surgery centers (ASCs) across 34 states — as the doorway into 25 additional markets. After closing, Ascension will run more than 300 ASCs, the country's third-largest ASC platform, alongside 95 wholly owned hospitals and 26 joint ventures that make it the seventh-largest US health system by hospital footprint.

The purchase rested on the recovery Ascension had just reported: from fiscal 2024 to 2025 the $25 billion nonprofit logged a $1.3 billion operating margin improvement and lifted recurring operating EBITDA from a $62 million loss to an $837 million gain, with length of stay down 5.4% and contract labor down 44% — despite massive cyberattack disruptions. Horizontal groups such as ASCs and specialty pharmacy grew EBITDA from $276 million in fiscal 2022 to $466 million in fiscal 2025, and 11 completed deals fueled over $575 million of operating income while de-levering about $1 billion.

Conrado's playbook for the 25 new markets is asset-light: no new or acquired acute-care hospitals — instead the ASC sites win referrals from independent physicians and serve as the ASC of choice for local health systems. In its 10 existing markets, the AmSurg sites help Ascension shift low-acuity cases out of hospitals to lower-cost settings patients prefer, lifting case mix where it invests in clinical programs, while new wholly owned ASCs on its home turf prepare for a likely influx of uninsured patients. He cited a 10%-plus ambulatory CAGR against roughly 3% for acute care in its markets.

FY25 recurring operating EBITDA swung from -$62M to +$837M on a $1.3B margin improvement; the deal adds 250-plus ASCs across 34 states.

Ascension spent much of the prior two years trimming its acute-care presence outside core regions; AmSurg turns that ambulatory pivot from retreat into offense.

The ambulatory space carries a 10%-plus CAGR by Conrado's estimate, against about 3% for acute markets Ascension already serves.

The fiscal 2025 recovery — a $1.3B margin swing and EBITDA from -$62M to +$837M — gave the nonprofit the credibility and balance-sheet room for a $3.9B purchase.

Owning a top-three ASC platform lets Ascension move low-acuity cases out of its hospitals, cutting costs and raising case mix where it invests in clinical programs.

A turnaround buys the room to go back on offense: sell what you no longer need to own, then buy the growth platform that fits where your industry is heading.

The acquisition was still pending close when Conrado spoke in January 2026. Ascension guided to a 0.5% operating income margin for the current fiscal year, roughly 2% for fiscal 2027 and about 3% for fiscal 2028 from current operations, rising to about 4% — roughly $1.1 to $1.2 billion of operating income — once planned M&A, led by AmSurg, is included. New wholly owned ASCs are planned on its home turf, and Conrado argued the diversified portfolio positions the system to absorb a likely influx of uninsured patients.